Background Lung cancer is the leading cause of cancer‐related deaths worldwide and the
prognosis remains poor. The recent introduction of the immune checkpoint inhibitor (ICI), or …

Immunotherapy in non-small cell lung cancer harbouring driver mutations - ScienceDirect Skip
to main contentSkip to article Elsevier logo Journals & Books Search RegisterSign in View …

As the leading cause of cancer death worldwide, lung cancer continues to impose a major
burden on healthcare systems and cause significant challenges for clinicians and patients …

The immune system plays a dual role in tumor evolution—it can identify and control nascent
tumor cells in a process called immunosurveillance and can promote tumor progression …

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment paradigm for lung
cancer in recent years. These strategies consist of neutralizing antibodies against negative …

Lung cancer is one of the most common cancer in the world. In 2018, there were over 2
million new cases of lung cancer and over 1.7 million deaths were attributed to lung cancer …

Different approaches for treating lung cancer have been developed over time, including
chemotherapy, radiotherapy and targeted therapies against activating mutations. Lately …

Immunotherapy for non-small cell lung cancer (NSCLC) is incorporated increasingly in first
line treatments protocols. Multiple phase 3 studies have tested different medications …

Lung cancer remains the leading cause of cancer related death worldwide. Despite broad
advances in diagnostics and therapy, the five-year overall survival for patients with …

Immuno-oncology has revolutionized the treatment of metastatic non-small cell lung cancer
(mNSCLC) since the approval of immunotherapy by the US FDA in 2015. Despite the …